Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

For over 20 years, I have relied on a CPAP machine to manage my sleep apnea—a life-threatening condition that, if left untreated, can cause serious complications, including death during sleep.

The Bitmain Antminer S21 Pro leads with 234 TH/s and advanced air cooling for efficient mining. Immersion-cooled ASICs like MicroBT M66S Immersion boost efficiency and extend hardware lifespan. The ...

If you click on links we provide, we may receive compensation. Best-selling options start at $44 A veteran journalist, Miles Walls is a quality team writer for Dotdash Meredith brands like PEOPLE ...

BOISE, Idaho—Brienna Hall has the most valuable role that you’ll never see at the most vital company that you’ve never heard of. Until she began working at ASML last year, she didn’t ...

This is a heartbreaking story out of Florida. Megan Garcia thought her 14-year-old son was spending all his time playing video games. She had no idea he was having abusive, in-depth and sexual ...

Given the concerns over delays in the completion of many National Highway projects across the country, the Ministry of Road Transport & Highways (MoRTH) has expedited the use of Automated & ...